Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing
- PMID: 38266942
- DOI: 10.1016/j.ijpharm.2024.123845
Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing
Abstract
CRISPR-Cas genome editing technology holds great promise for wide-ranging biomedical applications. However, the development of efficient delivery system for CRISPR-Cas components remains challenging. Herein, we synthesized a series of ionizable lipids by conjugation of alkyl-acrylate to different amine molecules and further assembled ionizable lipid nanoparticles (iLNPs) for co-delivery of Cas9 mRNA and sgRNA. Among all the iLNP candidates, 1A14-iLNP with lipids containing spermine as amine head, demonstrated the highest cellular uptake, endosomal escape and mRNA expression in vitro. Co-delivery of Cas9 mRNA and sgRNA targeting EGFP by 1A14-iLNP achieved the highest EGFP knockout efficiency up to 70% in HeLa-EGFP cells. In addition, 1A14-iLNP displayed passive liver-targeting delivery of Cas9 mRNA in vivo with good biocompatibility. Moreover, we developed a simple method of lyophilization-mediated reverse transfection of CRISPR-Cas9 components for efficient genome editing. Therefore, the developed 1A14-iLNP and the lyophilization formulation, represent a potent solution for CRISPR-Cas9 delivery, which might broaden the future of biomedical applications of both mRNA and CRISPR-based therapies.
Keywords: CRISPR-Cas9; Genome editing; Lipid nanoparticle; Lyophilization; mRNA delivery.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Boosting ionizable lipid nanoparticle-mediated in vivo mRNA delivery through optimization of lipid amine-head groups.Biomater Sci. 2021 Nov 9;9(22):7534-7546. doi: 10.1039/d1bm00866h. Biomater Sci. 2021. PMID: 34647548
-
Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.Adv Mater. 2019 Aug;31(33):e1902575. doi: 10.1002/adma.201902575. Epub 2019 Jun 19. Adv Mater. 2019. PMID: 31215123 Free PMC article.
-
Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA.Angew Chem Int Ed Engl. 2017 Jan 19;56(4):1059-1063. doi: 10.1002/anie.201610209. Epub 2016 Dec 16. Angew Chem Int Ed Engl. 2017. PMID: 27981708 Free PMC article.
-
Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.Chembiochem. 2023 May 2;24(9):e202200801. doi: 10.1002/cbic.202200801. Epub 2023 Mar 30. Chembiochem. 2023. PMID: 36780174 Review.
-
Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.Mol Pharm. 2022 Jun 6;19(6):1669-1686. doi: 10.1021/acs.molpharmaceut.1c00916. Epub 2022 May 20. Mol Pharm. 2022. PMID: 35594500 Free PMC article. Review.
Cited by
-
Improving the use of CRISPR/Cas9 gene editing machinery as a cancer therapeutic tool with the help of nanomedicine.3 Biotech. 2025 Jan;15(1):17. doi: 10.1007/s13205-024-04186-1. Epub 2024 Dec 19. 3 Biotech. 2025. PMID: 39711922 Review.
-
Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases.Mol Ther Nucleic Acids. 2025 Aug 5;36(3):102666. doi: 10.1016/j.omtn.2025.102666. eCollection 2025 Sep 9. Mol Ther Nucleic Acids. 2025. PMID: 40896588 Free PMC article. Review.
-
CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations.Molecules. 2025 Jan 24;30(3):542. doi: 10.3390/molecules30030542. Molecules. 2025. PMID: 39942646 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources